Get the composition of our in-house portfolios

All portfolios and performance
Portfolio Ref: EQ3515LS2W
Performance in the last:
Follow this Portfolio
1D -0.3 %
1W -0.6 %
2W -0.6 %
1M 3.8 %
3M 11.2 %
6M -68.6 %
9M -64.7 %
1Y -67.6 %
Alpha
-80.2%
Beta
0.47
sharpe-R
-0.85
Benchmark
SP500 (SPDR S&P 500 ETF Trust)
sharpe-R Benchmark
2.12
The portfolio metrics Alpha, Beta and Sharpe Ratio are computed using a risk free rate of 0%.
Other Information
Calculation Frequency Daily
Latest Valuation Time 2024-09-16 06:53:46
Launch Date 2023-01-01 00:00:00
First Valuation Date 2021-01-01 00:00:00
Max. DrawDown -75.48%
Max. DrawDown Benchmark -8.41%

This Long-Short strategy aims to find promising assets to invest in for a maximum holding period of 2 Weeks in the Equity asset class. This portfolio focuses only on companies in the Health Care sector. The maximum number of assets that can be allocated in this strategy is 15.

The assets selection in this portfolio is based on: Macro-Pattern Mix St..
Please note that all model portfolios assume that the entry price for each trade is the previous close price.

For Long-Short model portfolios, the short-selling costs (asset borrowing costs) are not taken into account. This assumption is likely unrealistic, and it is important to understand the short-selling process before employing this type of strategy.

Portfolio Performance against the market Benchmark

Try Our Peformance Checker Tool

Risk Level
3
Difficulty Level
4

Do you want to invest in this strategy ?

Follow the portfolio and you will get notified for every change in the composition of the portfolio

Current Portfolio Composition

Asset Asset Class Action Weight PnL
PDSB PDS Biotechnology Corporation Equity Buy 9.82% -0.33%
NVAX Novavax, Inc. Equity Buy 10.56% 7.17%
RGNX REGENXBIO Inc. Equity Buy 10.72% 1.02%
ESPR Esperion Therapeutics, Inc. Equity Buy 11.65% 9.77%
SRNE Sorrento Therapeutics, Inc. Equity Buy 8.7% -25%
AGEN Agenus Inc. Equity Buy 12.25% 5.56%
LLY Eli Lilly and Company Equity Buy 11.46% -1.21%
IRTC iRhythm Technologies, Inc. Equity Buy 13.59% 0%
TDOC Teladoc Health, Inc. Equity Buy 13.59% 0%
MRSN Mersana Therapeutics, Inc. Equity Buy 13.59% 0%
CARA Cara Therapeutics, Inc. Equity Sell -5.65% 6.41%
SIGA SIGA Technologies, Inc. Equity Sell -6.25% -5.19%
BGNE BeiGene, Ltd. Equity Sell -6.03% -1.13%
The percentage of cash held in the portfolio is: 2%
** The description of each asset is available Here

The latest 5 Compositions change

2024-09-16 00:00:00 : Portfolio change date
Asset Action Weight PnL
PDSB PDS Biotechnology Corporation Buy 9.82% -0.33%
NVAX Novavax, Inc. Buy 10.56% 7.17%
RGNX REGENXBIO Inc. Buy 10.72% 1.02%
ESPR Esperion Therapeutics, Inc. Buy 11.65% 9.77%
SRNE Sorrento Therapeutics, Inc. Buy 8.7% -25%
AGEN Agenus Inc. Buy 12.25% 5.56%
LLY Eli Lilly and Company Buy 11.46% -1.21%
IRTC iRhythm Technologies, Inc. Buy 13.59% 0%
TDOC Teladoc Health, Inc. Buy 13.59% 0%
MRSN Mersana Therapeutics, Inc. Buy 13.59% 0%
CARA Cara Therapeutics, Inc. Sell -5.65% 6.41%
SIGA SIGA Technologies, Inc. Sell -6.25% -5.19%
BGNE BeiGene, Ltd. Sell -6.03% -1.13%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • IRTC
  • TDOC
  • MRSN
Assets Removed
None
Assets Rebalanced
None
2024-09-13 00:00:00 : Portfolio change date
Asset Action Weight PnL
PDSB PDS Biotechnology Corporation Buy 10.02% 1.33%
NVAX Novavax, Inc. Buy 9.28% -6.14%
RGNX REGENXBIO Inc. Buy 10.2% -4.17%
ESPR Esperion Therapeutics, Inc. Buy 10.71% 0.57%
SRNE Sorrento Therapeutics, Inc. Buy 11.64% 0%
AGEN Agenus Inc. Buy 11.64% 0%
LLY Eli Lilly and Company Buy 11.64% 0%
CARA Cara Therapeutics, Inc. Sell -5.82% 3.91%
SIGA SIGA Technologies, Inc. Sell -6.25% -4.79%
BGNE BeiGene, Ltd. Sell -5.98% 0%
The percentage of cash held in the portfolio is: 42.9%
New Assets Added
  • SRNE
  • AGEN
  • LLY
  • BGNE
Assets Removed
None
Assets Rebalanced
None
2024-09-12 00:00:00 : Portfolio change date
Asset Action Weight PnL
PDSB PDS Biotechnology Corporation Buy 10.12% 2.99%
NVAX Novavax, Inc. Buy 9.51% -3.23%
RGNX REGENXBIO Inc. Buy 10.58% 0%
ESPR Esperion Therapeutics, Inc. Buy 10.58% 0%
CARA Cara Therapeutics, Inc. Sell -6.3% -4.63%
SIGA SIGA Technologies, Inc. Sell -5.93% 0%
The percentage of cash held in the portfolio is: 71.42%
New Assets Added
  • RGNX
  • ESPR
  • SIGA
Assets Removed
None
Assets Rebalanced
None
2024-09-11 00:00:00 : Portfolio change date
Asset Action Weight PnL
PDSB PDS Biotechnology Corporation Buy 9.8% 0%
NVAX Novavax, Inc. Buy 9.8% 0%
CARA Cara Therapeutics, Inc. Sell -6% 0%
The percentage of cash held in the portfolio is: 86.4%
New Assets Added
  • PDSB
  • NVAX
  • CARA
Assets Removed
None
Assets Rebalanced
None
2024-08-30 00:00:00 : Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is: 100%
New Assets Added
None
Assets Removed
Asset Action Perf %
KIDS Sell All 12.95%
Assets Rebalanced
None
2024-08-27 00:00:00 : Portfolio change date
Asset Action Weight PnL
KIDS OrthoPediatrics Corp. Buy 12.4% 15.23%
The percentage of cash held in the portfolio is: 87.6%
New Assets Added
None
Assets Removed
Asset Action Perf %
OFIX Buy All -7.98%
Assets Rebalanced
None

Load more previous compositions

Compositions In The Last 2W Compositions In The Last 1M Compositions In The Last 3M Compositions In The Last 6M

Market Overview

Disclaimer Quantam Research does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, assets forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
Cookies Settings